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Abstract
Background: Circulating monocytes are a highly plastic and functionally heterogeneic cell type with an activated
phenotype in patients with systemic sclerosis (SSc). CD14
+ monocytes have the potential to differentiate into extra-cellular
matrix (ECM) producing cells, possibly participating in fibrogenesis.
Aim: To study the effect of GM-CSF, IL-4 and endothelin -1 (ET-1) alone or in combination on monocyte differentiation into
myofibroblasts.
Methods: CD14
+ cells were isolated from peripheral blood from 14 SSc patients and healthy controls by positive selection
and incubated with different combinations of GM-CSF, IL-4 and ET-1 for 14 days. Type-1 collagen and a-SMA were detected
by Western blot, qPCR and confocal microscopy. HLA-DR, CD11c and CD14 expression was analysed by flow cytometry. A
collagen gel contraction assay was performed for functional myofibroblast assessment.
Results: GM-CSF both induced collagen and a-SMA expression after 14 days. ET-1 further increased GM-CSF-induced
collagen expression in a dose dependent manner up to 30-fold. IL-4/GM-CSF combination leads to a more DC-like
phenotype of monocytes associated with reduced collagen and a-SMA expression compared to GM-CSF alone. Collagen
and a-SMA expression was higher in monocytes from SSc patients and monocytes were more prone to obtain a spindle
form. In contrast to controls, ET-1 and IL-4 alone were sufficient to induce a-SMA expression in monocytes from SSc
patients. Despite the induction of a-SMA expression, monocyte-derived myofibroblasts only had a moderate capability of
contraction in functional analyses.
Conclusion: SSc monocytes display increased maturation towards myofibroblasts demonstrated by their phenotype and a-
SMA expression when compared to monocytes from healthy controls, however only with minor functional contraction
properties.
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Introduction
Systemic sclerosis (SSc) is an autoimmune multisystem connective
disease where low grade inflammation and vasculopathy lead to
increased extracellular matrix (ECM) deposition in affected tissues,
notably the skin, lungs and gastrointestinal tract [1,2]. Inflammation
in SSc is characterized by the infiltration of monocytes, notably in
the early phase of the disease [3]. CD14
+ monocytes are bone
marrow derived, highly plastic and functionally heterogeneous cells.
Apart from their well known capacity to differentiate into dendritic
cells (DC) and macrophages, they also have the potential to
differentiate into collagen-producing fibrocytes [4] or other cells
sharing characteristics of cells with mesenchymal or ectodermal
origin[5].InSScpatients,circulatingCD14
+monocytenumbersare
increased, with an activated status demonstrated by their expression
of CD68, CD204 and Siglec-1 [6–8]. Collagen-expressing
CD14
+CD34
+ fibrocytes have been found in higher numbers in
lungs of patients with SSc-associated interstitial lung disease [9] and
fibrocyte recruitment to the skin has been demonstrated in the
bleomycin mouse model [10].
Myofibroblasts arekey effectorcells in fibrosisby their capacityto
synthesize collagen and contractile a-smooth muscle actin (SMA).
Myofibroblasts differentiate either directly from fibroblasts e.g.
under the influence of TGF-beta or Endothelin-1 (ET-1) [11,12],
from epithelial cells via epithelial mesenchymal transition (EMT)
[13] or from fibrocytes [14]. In atherosclerosis models it has been
demonstrated that haematopoietic cells can differentiate into a-
SMA producing cells, actively promoting intima fibrosis [15].
Granulocyte-macrophage colony-stimulating factor (GM-CSF)
is the main differentiation factor for monocytes [16]. GM-CSF is
PLoS ONE | www.plosone.org 1 March 2012 | Volume 7 | Issue 3 | e33508produced by a variety of cell types including T- and B-
lymphocytes, macrophages and endothelial cells [17]. The
combination of GM-CSF in combination with IL-4 is commonly
used to differentiate monocytes into DC. GM-CSF is required for
in vitro monocyte survival, proliferation and as trigger of
macrophage differentiation, whereas the combination with IL-4
drives differentiation of monocytes into DC [18]. In vitro culture of
monocytes in the presence of GM-CSF for a prolonged time
stimulates the formation of CD14
low cells with a DC morphology
and high viability, expressing HLA-DR, CD86 and CD11a but
low CD1a [19]. These cells are refractory to maturation induced
by inflammatory stimuli, thus showing a more regulatory character
than classical, IL-4 driven inflammatory DC. Upon subcutaneous
injection, GM-CSF leads initially to the infiltration of macro-
phages; after chronic administration, GM-CSF induces fibrotic
responses with accumulation of a-SMA -expressing myofibroblasts
[20]. GM-CSF levels rise during inflammation [21] and are higher
in bronchoalveolar lavage fluid from patients with idiopathic
pulmonary fibrosis compared to healthy controls [22]. Similar to
the described overexpression of GM-CSF-receptors on SSc
fibroblasts [23], GM-CSF–receptors are also upregulated on
mononuclear cells infiltrates in scar formation [24].
ET-1 plays an important pathogenic role in SSc. ET-1, which is
highly expressed in vessels, acts as vasoconstrictor but is also known for
its function as differentiation factor [25]. The effect of ET-1 has
mainly been studied on fibroblasts where ET-1 both stimulates a-
SMA production and collagen matrix contraction. In SSc, ET-1 is
overexpressed by endothelial cells and fibroblasts, as compared to
healthy controls [26].
We hypothesised that activated monocytes from SSc patients
have a dysregulated differentiation potential upon stimulation with
GM-CSF, IL-4 and also ET-1 into ECM producing, myofibro-
blast-like cells, thereby participating in fibrosis.
Materials and Methods
Patients
Peripheralblood wascollected from14 patientswithlimited (n=9)
or diffuse (n=5 ) SSc (1 male and 13 females; age 45–83 years, mean
6 SD 62.2612.3 years). The mean disease duration was 8.6 years
(range 2–20 years). Six patients were on treatment with immuno-
suppressive medication. Patient characteristics are summarized in
Table 1. Control blood samples were obtained anonymously from the
blood center Newcastle in accordance with ethical regulations in the
UK. The protocol was approved by Newcastle University Joint
Research Office and the National Research Ethics Service and
written informed consent has been obtained from the patients.
Monocyte isolation and cultivation
PBMCs were isolated from peripheral blood from SSc patients
or anonymised healthy controls (n=8) using Lymphoprep
TM
(Axis-Shield, Olso, Norway). Monocytes were isolated from the
PBMC fraction using CD14 microbeads (Miltenyi, Bergisch-
Gladbach, Germany). Monocytes were seeded into tissue culture
plates in a density of 1610
6 cells per ml and treated for 14 days
with 50 ng/ml GM-CSF, 50 ng/ml IL-4 (both Immunotools,
Friesoythe, Germany) or 0–500 ng/ml ET-1 (Calbiochem, Merck,
Darmstadt, Germany). The culture medium was replenished every
3 days. Light microscopy was used to observe morphological
changes. For quantification, spindle shaped cells per 565 cm field
were counted and normalized to the cell number.
Western blotting
Total cell extracts were prepared in 20 mM Tris (pH 7.5), 1 mM
EDTA, 100 mM NaCl, 1% Trition X-100, 0,5% Desoxycholate,
0,1% SDS and Protease inhibtor cocktail (Roche, Welwyn Garden
City, UK). Protein extracts were subsequently separated by SDS-
PAGEon 4–20%gradient gels (Bio-Rad, Hercules,CA)and blotted
onPVDFmembranes.Todetectproteins,Westernblotanalysiswas
performed using anti-type 1 collagen, anti-alpha SMA (both
Millipore, Temecula, USA), anti-vimentin (DAKO) and anti-
GAPDH antibodies (HyTest, Turku, Finnland). Western Blots
were quantified by using ImageJ software.
Confocal microscopy
For immunfluorescence staining 1.5610
5 monocytes were seeded
in 8-well Culture slides (BD Falcon, Oxford, UK) and cultured for
Table 1. Patient characteristics.
Age/Gender Disease subtype Disease duration (years) Auto-Antibody Immuno-supessive treament
77/f Limited 12 ANA -
68/f Limited 1 ACA AZA
60/f Diffuse 2 ANA -
57/f Limited 7 ACA -
60/f Limited 2 ANA -
64/f Diffuse 11 nd nd
62/f Limited 11 nd -
45/f Limited 11 ACA -
63/m Diffuse 5 - Cyc, MMF
72/f Limited 17 ACA -
38/f Diffuse 2 - Cyc, MMF
83/f Limited 11 - Penicillamine
50/f Limited 7 - MTX
60/f Diffuse 20 Scl-70 Cyc
Abbreviations: f:female, m:male, ANA: anti-nuclear antibodies; ACA: anti-centromere antibodies; nd: no data, AZA, azathioprine, Cyc: cyclophosphamide, MMF:
mycophenolate mofetil, MTX: methotrexate.
doi:10.1371/journal.pone.0033508.t001
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with 0.02% Triton X-100 cells were blocked in 10% goat serum.
Specimens were stained with anti-a-SMA (Millipore, Temecula,
USA) and 49,6-Diamidine-29-phenylindole dihydrochloride (DAPI)
(Roche Applied Science, Burgess Hill, UK) and mounted in Mowiol
4–88 (Sigma Aldrich, UK). For imaging of the slides a Leica SP2
AOBS UV confocal microscope with a 636oil immersion objective
was used.
Procollagen expression
Quantitative assessment of mRNA expression levels was achieved
by 2-step real-time PCR (qRT-PCR). Total RNAwas extracted using
the RNeasy Mini Kit (Qiagen, Crawley, UK). Reverse transcription
of mRNA into cDNA from 0.5–1 mgo ft h ee x t r a c t e dt o t a lR N Aw a s
conducted using the QuantiTect RT Kit (Qiagen). Subsequently, the
cDNA was subjected to qRT-PCR in triplicate using the ABi HT
7900 system (Applied Biosystems, USA) and the nonspecific DNA
binding dye SYBR green I for the detection of PCR products (SYBR
Green real-timePCRKit from Sigma Aldrich, UK). Procollagen was
amplified with gene-specific oligonucleotide primer pairs (forward 59-
CAA GAG GAA GGC CAA GTC GAG G -39, reverse 59-CGT
T G TC G CA G AC G CA G AT- 3 9). To quantify the relative
expression levels of these genes, the expression of 18S mRNA was
also determined in the same cDNA samples using a gene-specific
primer pair (forward 59 CGA ATG GCT CAT TAA ATC AGT
TAT GG-39 reverse 59-TAT TAG CTC TAG AAT TAC CAC
AGT TAT CC-39).
Collagen-gel contraction assay
Collagen gels were prepared as described elsewhere [27]. Briefly,
0.5610
6 monocytes wereseededon the collagen gels and stimulated
as describes above with GM-CSF, IL-4 or ET-1. Pictures where
take with the Syngene G:Box imaging system and the gel area was
calculated using Image J software.
Statistical analysis
All data were evaluated using Student t-test. For non-parametric
analysis, Mann Withney U and Kruskal Wallis tests were applied.
P-values,0.05 were considered statistically significant. Results are
shown as mean and standard error of the means.
Results
CD14
+ monocytes differentiate into type-1 collagen and
a-SMA expressing cells in the presence of GM-CSF
To study the differentiation potential of monocytes into
myofibroblasts, the expression of a-SMA as a myofibroblast marker
and type-1 collagen was determined by western blot analysis.
Monocytes cultured for 14 days solely in medium and 10% FCS did
not express collagen or a-SMA (Figure 1A). The presence of GM-
CSF induced expression both of a-SMA and type-1 collagen. We
detected collagen expression after 7 days and a-SMA after 14 days
(data not shown). The addition of ET-1 to GM-CSF further
increased collagen and to a lesser extent a-SMA expression, whereas
IL-4 in addition to GM-CSF reduced a-SMA and prevented
collagen expression. The combination of IL-4 and ET-1 without
GM-CSF weakly induced a-SMA, but not collagen expression.
ET-1 upregulates GM-CSF-induced type-1 collagen
expression in a dose-dependent manner
We incubated CD14
+ cells from healthy individuals for 14 days in
the presence of 50 ng/ml GM-CSF and increasing doses of ET-1
from 0–500 ng/ml (Figure 1B). In relation to GAPDH, collagen
expression increased in the presence of ET-1. The highest collagen
levels corresponding a nearly 30-fold increased expression were
observed at an ET-1 concentration of 100 ng/ml (Figure 1C).
Conversely,ET-1leadonlytoa2-folda-SMAexpression(Figure1D).
Phenotype of cultured monocytes in the presence of
GM-CSF, IL-4 and or IL-4
We analysed the phenotype of the monocytes after 14 days
culture in the presence of different combinations of GM-CSF, ET-
1 (100 ng/ml) and IL-4 by flow cytometry (Figure 1E). IL-4 with
or without ET-1 added to GM-CSF lead to a higher expression of
HLA-DR, and to a lesser extent also CD11c, as compared to GM-
CSF alone or GM-CSF and ET-1. CD14 expression was lost
during the time of culture albeit CD14 expression was partly
preserved in the presence of IL-4, altogether suggesting a more
DC-like phenotype in the presence of IL-4.
Type-1 collagen and a-SMA expression is higher in
monocytes from SSc patients
5610
5 CD14
+ monocytes were isolated from patients with SSc
and healthy controls and incubated for 14 days according previous
experiments in medium supplemented with 10% FCS and
different combinations of ET-1, GM-CSF and IL-4. GM-CSF-
induced a-SMA expression appeared higher in samples from SSc
patients (Figure 2A). In contrast to healthy samples, a-SMA was
induced in SSc monocytes which were stimulated by ET-1 or IL-4
alone. ET-1/GM-CSF, IL-4/GM-CSF and ET-1/GM-CSF/IL-4
combination induced a higher a-SMA expression in SSc patients
compared to healthy controls (Figure 2B), although no statistical
significance could be detected between the subgroups.
Baseline expression of procollagen as measured by qPCR was
only detected in the presence of GM-CSF. GM-CSF-induced
collagen expression was significantly higher in SSc monocytes
(p,0.05) (Figure 2C). The addition of ET-1 to GM-CSF resulted in
a 10-fold increase collagen expression in both in monocytes from
healthy controls (Figure 2D) and SSc patients (Figure 2E). Similar to
our findings with a-SMA, the addition of IL-4 to GM-CSF also
reduced collagen expression. We did not observe a difference in a-
SMA or collagen expression between patients with limited or diffuse
SSc subtypes (data not shown). As a third myofibroblast structural
protein we determined vimentin expression by Western blotting in
cultured monocytes. Unlike type-1 collagen and a-SMA, vimentin
expression was observed in untreated monocytes after 14 (Figure
S1). Similar to collagen and a-SMA, GM-CSF was the strongest
factor for induction of vimentin expression, both in monocytes from
SSc patients and healthy controls.
Monocytes from SSc patients obtain a more spindled shape
For a morphological analysis, we stained healthy or SSc
monocytes incubated with GM-CSF for 14 days with a-SMA
antiserum for confocal microscopy. We found that monocytes
from SSc patients expressed more a-SMA and obtained a more
spindled shape than monocytes from healthy controls (Figure 3A).
After normalization to cell numbers, the relative number of spindle
shaped cells per 565 cm field was significantly higher in
monocytes from SSc patients (p,0.001) (Figure 3B).
Functional collagen-gel contraction anlaysis
For functional assessment of contraction, we seeded 5610
5 CD14
+
monocytes on collagen gels under before mentioned conditions with
GM-CSF, IL-4or ET-1 (Figure 4A). Fibroblasts were used as positive
controls and yielded a 97,6% contraction of the gel after 14 days.
Monocyte-induced myofibroblasts contracted the collagen gel at a
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monocytes and a maximum of 5% contraction with untreated
monocytes. The strongest contraction was observed in cells treated
with ET-1 and GM-CSF (Figure 4B). No significant difference of
contraction was detectable between healthy and SSc monocytes.
Discussion
This proof-of-concept study demonstrates the differentiation
potential of monocytes in the direction of myofibroblasts in SSc
patients and healthy controls under the influence of GM-CSF, ET-
1 or IL-4. Monocytes from SSc patients were more prone to
differentiate into myofibroblasts, as demonstrated by significantly
higher levels of collagen expression, spindle-shaped myofibroblast-
like cell morphology and a trend towards higher a-SMA
production, compared to healthy control monocytes. Matrix
production of cultured SSc monocytes and the morphological
difference provides further evidence that monocytes may play an
important role in SSc fibrogenesis. We postulate that myofibro-
blasts, which are often encountered perivascularly in SSc tissue,
are chemokine-attracted, extravasated cells potentially originating
from the large pool of circulating monocytes. The previously
described alternatively activated status of SSc monocytes and their
impaired subset distribution in the peripheral blood might account
for our observations. To this end, further studies will be necessary
to clarify the differentiation potential of e.g. CD14
+16
+ monocyte
subset into myofibroblasts.
To our knowledge, we provide the first evidence that the
prolonged culture of healthy monocytes with GM-CSF exhibits
Figure 1. Healthy monocytes can differentiate into a-SMA and collagen expressing cells upon GM-CSF stimulation. A) CD14
+
monocytes from healthy donors were cultured for 14 days with GM-CSF, IL-4 or ET-1. Western blot analysis showed expression of type-1 collagen and
a-SMA under distinct conditions. Fibroblasts were used as a positive control, GAPDH was used as loading control. B) Monocytes were treated with
GM-CSF and 0–500 ng/ml of ET-1 over 14 days. Western Blot analysis for type-1 collagen and a-SMA was conducted. GAPDH was used as loading
control. C) and D) Quantification of the western blots from 3 independent experiments are shown. E) Expression of CD14, HLA-DR and CD11c was
assessed by flow cytometry.
doi:10.1371/journal.pone.0033508.g001
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were cultured for 14 days with GM-CSF, IL-4 or ET-1. a-SMA levels were detected by Western blot analysis. GAPDH was used as loading control. B)
Quantification of Western blots from 8 patients and 8 healthy controls showed stronger expression of a-SMA in SSc monocytes compared to healthy
controls despite no significant difference could be detected. C) qPCR analysis of the procollagen expression in GM-CSF treated monocytes from
healthy controls (HC) (n=4) or SSc patients (n=8). Data were normalized to expression of 18S. (p=0.481). D) and E) Monocytes from HC (n=4) and
SSc patients (n=3) were treated with various combinations of GM-CSF, IL-4 and ET-1. Procollagen expression was measured by qPCR. Data were
normalized to expression of 18S. The concentration of ET-1 in all experiments was 100 ng/ml. * Statistically significant (P-value,0.05).
doi:10.1371/journal.pone.0033508.g002
Figure 3. Morphological analysis of monocytes from SSc patients and healthy controls. A) Immunofluorescence staining of a-SMA (red) in
GM-CSF treated monocytes from healthy control or a SSc patient. Fibroblasts were used as positive control. Nuclei were stained with DAPI (blue). For
quantification, spindle shaped cells per 565 cm field were counted and normalized to cell numbers (B). ** Statistically highly significant
(P-value,0.01).
doi:10.1371/journal.pone.0033508.g003
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recognized pathogenic effect in SSc, we added ET-1 as another
cell differentiation factor to panel. By the analysis of GM-CSF,
ET-1 and IL-4 alone and in combination we aimed to investigate a
more physiological setting rather than observing the effect of single
cytokines or differentiation factors. GM-CSF clearly turned out as
the strongest inducer of a-SMA, collagen and also vimentin as a
third cytoskeletal protein. GM-CSF-induced collagen expression
was further stimulated by ET-1 in a dose dependent manner, but
inhibited by IL-4. Similarly, in healthy individuals, GM-CSF-
induced a-SMA expression was moderately stimulated by ET-1,
but reduced in the presence of IL-4. In monocytes derived from
SSc patients, and the presence of GM-CSF, both ET-1 and IL-4
slightly decreased a-SMA production. However, unlike in healthy
monocytes, IL-4 and ET-1 alone or in combination induced a-
SMA expression in SSc monocytes. The latter finding is in line
with findings in fibroblasts, where IL-4 also has a stimulating effect
on a-SMA expression [28] suggesting that monocytes-derived
myofibroblasts from SSc patients share characteristics with
fibroblasts. The inhibitory effect of IL-4 and ET-1 on a-SMA
expression in combination with GM-CSF possibly is due
competitive inhibition within subcellular signalling pathways, e.g.
NF-kB, similar to observations in keratinocytes [29], or alterna-
tively, a shift of their phenotype towards DC.
Phenotype analysis by flow cytometry revealed that monocytes
cultured with IL-4 express higher of levels HLA-DR, and slightly
higher levels of CD11c. CD14
+ monocytes loose CD14 during
culture, albeit to a lesser extent in the presence of IL-4. This
confirms a more DC-like phenotype in an IL-4 condition, and thus
might explain the lower a-SMA and collagen expression in this
circumstance. As CD34
+ expression has not been tested, we can
not clarify to what extent monocyte-derived myofibroblasts under
these conditions correspond to fibrocytes. Furthermore, we did not
address in this study the question whether our observations are due
to selective outgrowth of a monocyte subtype such as fibrocytes or
CD16
+ monocytes, or whether all monocytes are equally affected
by an altered differentiation potential. It is likely that the increased
amount of CD14
+CD16
++ monocytes observed in the elderly react
differently on GM-CSF, IL-4 or ET-1 stimulation. The age
difference between patients and healthy controls therefore could
influence our observations. As a further limitation, monocytes
from patients suffering from non-fibrosing disorders have not been
analysed. A difference of apoptosis between healthy and SSc
monocytes could underlie the reduced a-SMA expression in
healthy controls; we therefore tested the difference of apoptosis in
SSc patients versus healthy controls after 14 days of culture by flow
cytometry and did not find a significant difference (data not
shown). In our experiments, GM-CSF, IL-4 or ET-1 stimulation
led to a different expression pattern between type-1 collagen and
a-SMA. Further studies are needed to determine whether this
reflects outgrowth of different cellular subsets. To confirm the
functional relevance of monocyte differentiation we performed
contractility assays which showed that monocyte-derived myofi-
broblasts result in a maximum of 30% contraction of collagen gelx,
Figure 4. GM-CSF treated monocytes are partially contractile. 5610
6 CD14
+ monocytes from SSc patients or healthy controls were seeded on
collagen gels and cultured for 14 days under different conditions as indicated. On day 14, the reduction of the gel area was calculated as percent of
the initial seize. B) The graph shows the summary of data from 4 healthy controls and 4 SSc patients. A significant difference between the two groups
was not detectable.
doi:10.1371/journal.pone.0033508.g004
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a 95% contraction by fibroblasts, the contractile property of
monocyte-derived myofibroblast is modest. We also could not
detect a clear difference between monocyte derived myofibroblasts
from SSc patients and healthy individuals, respectively. Possible
explanations for this partial effect could be the lower size of the
myofibroblasts compared to fibroblasts with an impaired fiber
architecture and the necessity of a further contractile stimulus after
the differentiation process. However, this finding also shows that
the differentiation process from monocytes into myofibroblast
under the tested conditions is not complete and that it might
require additional stimulation or further differentiation in vivo.
Nevertheless, our findings do show a potential of monocytes to
differentiate into spindle formed myofibroblasts with a higher
expression of matrix proteins which suggest that albeit reduced
functional properties, these cells are involved in SSc associated
fibrosis, vasculopathy or skin contractions and that notably GM-
CSF is a key player in this differentiation process. In future studies,
the differentiation potential of monocytes in SSc has to be
characterized by functional analyses and compared with the
histological analysis and serum levels of GM-CSF, ET-1 and IL-4
in the same individuals.
Supporting Information
Figure S1 GM-CSF upregulates Vimentin in monocytes
from SSc patients and healthy controls. Monocytes from
healthy controls or SSc patients were cultured for 14 days with
GM-CSF, IL-4 or ET-1. Vimentin levels were detected by
Western blot analysis. GAPDH was used as loading control.
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